Gaps in information about breast cancer risk and prevention impact African American women
https://www.facingourrisk.org/XRAY/Gaps-info-breast-cancer-prevention-African-American-women
Full article: https://www.tandfonline.com/doi/abs/10.1080/13557858.2018.1562053?journalCode=ceth20
A study showed that African American women with increased breast cancer risk experienced greater burdens in obtaining information at each step compared to white women. Racial differences in preventive choices correlated with differences in information and provider access. (3/14/19)
Questions To Ask Your Health Care Provider
- Am I a candidate for genetic testing? If so, how do I get tested?
- How do I consult a specialist about my breast cancer risk?
- What preventive options are available to me for reducing my risk of breast cancer?
- What are the pros and cons of different risk-reducing choices?
Open Clinical Trials
The following clinical research studies focus on addressing health disparities in cancer.
- NCT04854304: Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts. This study is looking at how effectively a FAST breast MRI can successfully detect breast cancer in Black women with dense breasts.
- NCT03640208: Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans. This research will study a community-based intervention to educate and overcome barriers to screening among African Americans who are 45 years or older with no personal or family history of colorectal cancer or inflammatory bowel disease.
- NCT04392050: A Community-Based Educational Intervention to Improve Colorectal Cancer Screening. This study will look at what makes it easy or difficult for underserved populations to have colorectal cancer screenings, with a focus on African American, Latinx and Asian people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.